Human platelets express two P2Y receptors: Gq-coupled P2Y 1 and Gi-coupled P2Y 12 .
Introduction
Extracellular nucleotides influence many biological functions, including vascular tone, cell division, cardiac and skeletal muscle contraction, platelet aggregation, as well as peripheral and central neurotransmission (Burnstock, 2004) . Adenosine triphosphate (ATP) and adenosine diphosphate (ADP) are released from several sources in the body, including purinergic nerve endings, platelets, chromaffin cells, and endothelial cells (Gordon, 1986) . Extracellular nucleotides can trigger intracellular effects by specifically binding to and activating cell surface membrane proteins known as P2 receptors (Burnstock, 2004; Dubyak and Cowen, 1990) . Two main families of receptors for extracellular nucleotides have been described: P2X receptors, which are ligand-gated ion channels, and P2Y receptors, which belong to the super family of G protein-coupled receptors (GPCRs) (Burnstock, 2004) . Eight distinct P2Y receptors are expressed in human tissues: P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2Y 11 , P2Y 12 , P2Y 13 , and P2Y 14 (Abbracchio et al., 2003; Burnstock, 2004) . Pharmacologically, P2Y receptors can be subdivided into five Gq-coupled subtypes (P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , and P2Y 11 ) and three Gi-coupled subtypes (P2Y 12 , P2Y 13 , and P2Y 14 ) . In addition, P2Y 11 receptor can also couple to Gs to activate adenylyl cyclase, and P2Y 2 can activate Gi-dependent pathway (Meshki et al., 2004) .
Of the P2Y receptors, Gq-coupled P2Y are found in human platelets and are the receptors of ADP, which plays an important role in platelet activation and therefore in hemostasis and thrombosis (Hollopeter et al., 2001; Leon et al., 2004; Leon et al., 1999; Zhang et al., 2001 ). Co-stimulation of both P2Y 1 and P2Y 12 is This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on October 18, 2005 as DOI: 10.1124 at ASPET Journals on January 6, 2018 molpharm.aspetjournals.org Downloaded from essential for ADP-induced platelet aggregation and thromboxane generation Jin et al., 2002) . The P2Y 12 receptor generally potentiates other agonistinduced platelet functional responses including dense granule release (Dangelmaier et al., 2001; Storey et al., 2000) . In addition, downstream signaling events from the P2Y 12 receptor are essential for Akt activation by other agonists in platelets (Kim et al., 2004) .
Of the two P2Y receptors found in human platelets, P2Y 1 receptor is ubiquitously expressed in tissues whereas P2Y 12 receptor is almost exclusively found in human platelets and brain glioma cells and most extensively studied in platelets (Zhang et al., 2001 ). P2Y 12 receptor plays a central role in platelet activation (Dorsam and Kunapuli, 2004 ) and therefore attracts tremendous interest from pharmaceutical companies to develop P2Y 12 antagonist as potential antithrombotic agents .
Clopidogrel and ticlopidine (Yoneda et al., 2004) are the two thienopyridine compounds widely used as antithrombotic drugs that target platelet P2Y 12 receptor, with clopidogel exhibiting overall benefits than aspirin in the prevention and treatment of thrombotic events. CS-747 is another more potent thienopyridine antithrombotic agent targeting the platelet P2Y 12 receptor that exerts its role via hepatic metabolism that is currently under clinical trial (Niitsu et al., 2005; Sugidachi et al., 2000; Sugidachi et al., 2001) . The AR-C compounds are another series of P2Y 12 receptor antagonists that directly block the platelet P2Y 12 receptor Vasiljev et al., 2003) .
As members of the GPCR superfamily, both P2Y 1 and P2Y 12 share the common overall structure feature of GPCRs. Both these receptors are encoded on chromosome 3, suggesting gene duplication. Furthermore, the P2Y 1 and P2Y 12 receptors have identical This article has not been copyedited and formatted. The final version may differ from this version. (Ding et al., 2005 ) Hoffmann et al., 1999; Jiang et al., 1997) . Clopidogrel, for example, targets the extracellular cysteines of the P2Y 12 receptor (Savi et al., 2001 ). In addition, several small molecule antagonists at the P2Y 12 receptor such as AR-C69931MX have been developed as potential anti-thrombotic drugs (Huang et al., 2000; Jacobsson et al., 2002 ).
In the past decade, the discovery of constitutive activity of GPCRs has provided a significant contribution to our understanding of receptor activation and drug action at molecular levels. Numerous constitutively active GPCRs have been described in natural or recombinant systems and some GPCRs with constitutive activity have been reported to be disease-causing. According to the two-state model, GPCRs exist in a balance between two functionally and conformationally different states: an inactive state (R) and an active state (R*) capable of activating G proteins in the absence of ligands. The basal level of receptor activity is determined by the proportion of the R* state. The classical agonists have a high affinity for R* and shift the balance to the R* state resulting in an increase of G protein activity, whereas the inverse agonists have a high affinity for R and shift the balance to R leading to the decrease of G protein activity. Neutral competitive antagonists bind both R and R* equally and do not displace the balance but can competitively antagonize the effects of both agonists and inverse agonists. Some mutations of the This article has not been copyedited and formatted. The final version may differ from this version. GPCR can also shift the balance to the R* state, increasing G protein activity in the absence of agonists and leading to constitutive activation of GPCRs.
In our attempt to identify the Gq-coupling domain of the human P2Y 1 receptor, we found that the C-terminus of the P2Y 1 receptor is essential for Gq coupling and further identified two Arg residues essential for Gq activation (Ding et al., 2005) . To further study the role of the P2Y 1 receptor C-terminus, we introduced human P2Y 1 receptor Cterminus into human P2Y 12 receptor to explore whether the P2Y 1 receptor C-terminus is sufficient for Gq coupling and therefore confer P2Y 12 receptor with Gq-coupling ability.
In this study, we report the constitutive activity of the chimeric P2Y 12 receptor with the P2Y 1 carboxyl terminus and the characterization of inverse and neutral antagonists at this receptor. To our knowledge, this is the first report of P2Y receptors with constitutive activity. The establishment of a cell line stably expressing a constitutively active mutant of P2Y 12 receptor may provide a useful tool to explore the inverse agonist activity of other P2Y 12 antagonists. 
Materials and Methods

Materials
K1 cells
The expression construct for the wild type P2Y 12 receptor or P2Y 12 /P2Y 12 chimera (1 µg) was used to transfect CHO-K1 cells using lipofectamine as described previously (Akbar et al., 1996) . The growth medium was replaced after 6 hours with fresh medium. Stable transfectants were selected on medium containing 400 µg/ml hygromycin or 500 µg/ml G418 and screened for the expression of wild type or chimeric P2Y 12 receptor by HA-tag detection via flow cytometry.
HA-tag detection by flow cytometry
CHO-K1 cells (naive, vector-transfected, or stably transfected with wild type or chimeric P2Y 12 receptors) were cultured in 100 mm dishes, washed twice with PBS (137 mM NaCl, 2.68 mM KCl, 4.29 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 ) and detached with Versene (0.5 mM Na 4 EDTA, 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , 15 mM KH 2 PO 4 , 1 mM glucose). After spinning at 700 rpm for 3 min, the pellets were resuspended in Tyrode's solution (137 mM NaCl, 2.67 mM KCl, 2 mM MgCl 2 , 2.03 mM NaH 2 PO4, 5.6 mM glucose, 10 mM Hepes, 0.2% bovine serum albumin, pH 7.4) and cell concentrations were adjusted to 10 7 /ml. Aliquots of 100 µl cell suspension were mixed with 4 µl of 1:10 diluted FITC-labeled monoclonal antibody against HA (Covance, Berkeley, CA) in the presence of 2 mM Ca 2+ . After incubation at 4°C for 1 hour in the This article has not been copyedited and formatted. The final version may differ from this version. 
Cyclic AMP assay
Intracellular Cyclic AMP assays were conducted by a modification of a previously described protocol . Briefly, cells were cultured in 6-well plates and labeled with 2 µL/mL [ 3 H]-adenine (74 kBq/mL) overnight at 37°C. The radiolabeling medium was replaced by fresh growth medium containing 0.5 mM IBMX (3-isobutyl-1-methylxanthine) and incubated for 10 minutes at 37°C. In the presence of 20 µM forskolin, various concentrations of agonist and antagonist were added and incubated at 37°C for 10 minutes unless indicated. The reactions were terminated by addition of 1 ml stop solution containing 5% trichloroacetic acid, 1 mM ATP and 1 mM cAMP. Cyclic AMP levels were determined and cAMP conversion from ATP was calculated as described by Berlot (Berlot, 1999) using the following formula: cAMP conversion from
Measurement of Phosphorylation of Akt
Phosphorylation of Akt in lysates from CHO-K1 cells stably expressing hP2Y 12 was estimated by immunoblotting using phospho-Akt (Ser 473 ) antibody (1:1000 dilution) (Cell Signaling) as described previously with some modification (Kim et al., 2004) . Cells grown in 6-well plates were stimulated with 2-MeSADP (1 µM) for 5 min at 37°C, and the reaction was stopped by washing with cold PBS and the addition of 250 µl of cold lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1µg/ml leupeptin, and 1 mM PMSF. In some experiments, cells were incubated overnight with 200 ng/ml pertussis toxin, a Gi inhibitor. Samples were boiled for 5 min, and proteins were separated on 10% SDS-PAGE and transferred onto 
Results
Construction and stable expression of wild type and chimeric human P2Y 12 receptor in CHO-K1 cells. A chimeric human P2Y 12 mutant with its C-terminus replaced by the corresponding human P2Y 1 receptor C-tail (Ding et al., 2005) was constructed by overlapping PCR and subsequently cloned into pcDNA3 (outlined in Fig. 1 ). The nucleotide sequence encoding the P2Y 12 /P2Y 1 chimera in the expression plasmid was This article has not been copyedited and formatted. The final version may differ from this version. Similarly, the wild type P2Y 12 receptor in pcDNA3.1/Hygro(+) was stably transfected into CHO-K1 cells, and one high expression clone (6-E11) was chosen after screening more than 60 stable clones resistant to 400 µg/ml hygromycin and designated P2Y 12 WT.
As shown in shown that the C-terminus of the human P2Y 1 receptor is essential for Gq coupling (Ding et al., 2005) . We also demonstrated that this P2Y 1 receptor C-terminus, when introduced This article has not been copyedited and formatted. The final version may differ from this version. (Ding et al., 2005) .
In order to address whether the chimeric P2Y 12 receptor still functions and activates Gi upon agonist stimulation, we evaluated 2-MeSADP-induced inhibition of adenylyl cyclase in chimeric P2Y 12 -expressing cells. We found that 2-MeSADP dose-dependently decreased cAMP levels in chimeric P2Y 12 -expressing cells stimulated with forskolin with an EC 50 of 0.15 ± 0.04 nM (Fig. 3A) , which is nearly equal to that of wild type P2Y 12 -expressing cells (EC 50 is 0.14 ± 0.03 nM) .
When forskolin-stimulated cAMP levels of the chimeric P2Y 12 receptor-expressing cells in the absence of P2Y 12 agonists were compared with that of the wild type P2Y 12 -expressing cells, we observed that the cAMP levels were markedly decreased in the chimeric P2Y 12 receptor-expressing cells compared with cells expressing the wild type P2Y 12 receptor (Fig. 3B) , suggesting that the chimeric P2Y 12 receptor is constitutively activated. The cAMP levels in chimeric P2Y 12 receptor-expressing cells in the absence of P2Y 12 agonists were about 28% of that in the wild type P2Y 12 -expressing cells, which is close to the maximal response induced by ADP or 2-MeSADP in wild type P2Y 12 -expressing cells . In order to confirm this constitutive activation of the Gi pathways, we used pertussis toxin (PTX), a Gi inhibitor. cAMP levels in the chimeric P2Y 12 receptor expressing cells were dramatically increased upon inhibition of Gi with PTX ( Fig. 3B) . However, PTX did not affect the cAMP levels in the cells expressing the wild type P2Y 12 receptor (Fig. 3B) . These results further confirmed that the chimeric P2Y 12 receptor constitutively activated the Gi pathways.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 4) . Similar to the effects on cAMP levels, this constitutive phosphorylation is PTX-sensitive and can be inhibited by PTX pretreatment (Fig. 4) . This further confirmed that the chimeric P2Y 12 receptor is constitutively activated and stimulates Gi pathways in the absence of an agonist.
Pharmacological characterization of the constitutively active P2Y 12 receptor. AR-C78511 is a selective P2Y 12 receptor antagonist Vasiljev et al., 2003) and the most potent of the 2-alkylthio-substituted ATP analogues (AR-C compounds)
developed by AstraZeneca targeting P2Y 12 receptor (Vasiljev et al., 2003) . In this study we found that AR-C78511 dose-dependently increased the basal cAMP levels of the P2Y 12 /P2Y 1 expressing cells with IC 50 of 17.4 ± 4.9 nM (Fig. 5A ). This is consistent with the reported pIC 50 of AR-C78511 to reverse 2-MeSADP-or ADP-induced response in rat and human platelets, as well as in C6-2B cells Vasiljev et al., 2003) . The maximal increase of intracellular cAMP over control ( This article has not been copyedited and formatted. The final version may differ from this version. (Collins and Hollidge, 2003; Huang et al., 2000; Ingall et al., 1999; Jacobsson et al., 2002) . We found that AR-C69931MX has no effects on the constitutive activity of the chimeric P2Y 12 up to 300 nM (Fig. 5A) . The efficacy of AR-C69931MX as a P2Y 12 receptor antagonist was confirmed by its effect antagonizing ADP-induced adenylyl cyclase inhibition in P2Y 12 wild type receptor-expressing cells (Fig. 5B ). Thus we conclude that AR-C69931MX is a neutral P2Y 12 antagonist.
As shown in Fig. 5A , AR-C69931MX at 300 nM did not demonstrate inverse agonistic activity on the constitutively active P2Y 12 mutant. However, at this concentration AR-C69931MX nearly completely reversed the increased cAMP level induced by 100 nM AR-C78511 (Fig. 5C ). This result further confirmed that AR-C69931MX is a pure antagonist while AR-C78511 is an inverse agonist on human P2Y 12 receptor.
AR-C66096, AR-C-67085 and AR-C69581 are other AR-C compounds developed by
AstraZeneca as potential antithrombotic drugs targeting platelet P2Y 12 receptor (Daniel et al., 1998; Humphries et al., 1994; Ingall et al., 1999; Vasiljev et al., 2003) . AR-C66096 has pK B of 7.6 on B10 cells (cAMP) (Simon et al., 2001 ) and a pK B value of 8.66 on ADP-induced human platelet aggregation (Humphries et al., 1994) . In this study we found that at 3 µM, which is more than 300-fold greater than that needed to completely This article has not been copyedited and formatted. The final version may differ from this version. We have compared the relative abilities of the AR-C compounds in a separate assay evaluating the phosphorylation of Akt downstream of the P2Y 12 receptor. As shown in (Vasiljev et al., 2003) .
Consistent with this pIC 50 , in this study we found that in the range of 100 nM through 3 µM, AR-C69581 concentration-dependently reversed ADP-induced adenylyl cyclase inhibition in CHO-K1 cells stably expressing P2Y 12 wild type receptor. Compared to its dramatic effects in antagonizing ADP-induced P2Y 12 activation at 1 µM and 3 µM, AR-C69581 exhibited only weak inverse agonistic activity toward the constitutively active mutant of P2Y 12 receptor at 3 µM (table 1) .
BzATP, a ADP receptor antagonist which antagonizes P2Y 12 receptor with a IC 50 of 116 ± 23 µM , concentration-dependently increased the cAMP level of the constitutively activated P2Y 12 mutant in the range of 100 µM -3000 µM, thus exhibiting its inverse agonistic activity at high concentration (data not shown).
Discussion
From a traditional point of view, GPCRs are activated upon agonist binding to its receptors; however, this concept has changed in the past decade. Numerous investigators have reported that GPCRs can be activated in the absence of agonists, i.e. constitutively activated. Constitutive activation can be induced by receptor overexpression or receptor mutation, which have been reported to be the causes of a variety of human diseases This article has not been copyedited and formatted. The final version may differ from this version. (Montanelli et al., 2004; Parfitt et al., 1996; Parma et al., 1993; Pearce et al., 1996; Smits et al., 2003) , such as familial syndrome of hypocalcemia with hypercalciuria hyperfunctioning (Pearce et al., 1996) , thyroid adenomas (Parma et al., 1993) , etc. To treat these diseases, the classical GPCRs antagonists that antagonize agonist binding to the receptors are ineffective while the inverse agonists are believed to have advantages (Lefkowitz, 2004) . Though numerous constitutively active GPCRs have been described in the past decade, no constitutive activation was reported in the P2Y subfamily including human platelet ADP receptors P2Y 1 and P2Y 12 .
We observed that replacement of the C-terminus of human P2Y 12 receptor with the corresponding part of human P2Y 1 receptor confers the mutated P2Y 12 high constitutive activity when stably expressed in CHO-K1 cells. At a similar expression level as the wild type P2Y 12 receptor, the basal level of the chimeric receptor activity is 3.6 fold higher than that of the wild type receptor as evaluated by adenylyl cyclase inhibition. Compared to other recombinant constitutively active receptor systems, for example, the constitutive activity of cholecystokinin type 2 receptor (CCK-2R) mutants which are 3% to 17% of the agonist-induced maximal response in the wild type receptor (Beinborn et al., 2004) , the constitutive activity of the chimeric P2Y 12 receptor is 88% of the agonist-induced maximal activity in the corresponding wild type receptor. Moreover, eliminating the activation of Gi protein through the addition of PTX abolished the constitutive activity of Inverse agonism is very common among GPCR antagonists (Kenakin, 2004) . At the α 1A adrenergic receptor, 5-hydroxytryptamine 2A receptor and histamine H1 receptor, the majority of the known antagonists are actually inverse agonists (Bakker et al., 2001; Rossier et al., 1999; Weiner et al., 2001) . Considering the therapeutic implication, it is suggested that all new antagonists should be routinely tested for their potential inverse agonistic activity in future drug development program (Behan and Chalmers, 2001; Chalmers and Behan, 2002; Seifert and Wenzel-Seifert, 2002) . Using the cell line expressing high constitutive activity of human P2Y 12 mutant, we further explored the This article has not been copyedited and formatted. The final version may differ from this version. inverse agonist activities of a series of P2Y 12 receptor antagonists including the AR-C compounds that were developed as potential antithrombotic drugs by AstraZeneca. Of the five AR-C compounds screened, AR-C78511 exhibits a potent full inverse agonist activity while AR-C69931MX is a pure P2Y 12 antagonist in the range of 0.1 nM -300 nM. AR-C69931MX completely antagonized the inverse agonist activity of AR-C78511, further confirming that AR-C78511 is an inverse agonist whereas AR-C69931MX is a pure antagonist.
The present results offer new perspectives on the functionality of the human P2Y 12
receptor and on the pharmacological properties of a selective P2Y 12 antagonist. Despite numerous disease-causing constitutively active mutations described in GPCRs, no constitutively active mutation leading to induction of thrombotic diseases have been reported to date. The identification of a constitutively active P2Y 12 mutation in this study raised the possibility that there may be unidentified constitutively active mutation of P2Y 12 receptor underlying some thrombotic disorders with unknown causes.
In conclusion, this is the first report of the constitutive activity of the human P2Y 12
receptor. The establishment of a cell line stably expressing the constitutively active human P2Y 12 receptor provides a very useful tool to study the inverse agonist activity of P2Y 12 receptor antagonists. Using the cell line we successfully identified a P2Y 12 receptor antagonist with potent inverse agonist activity that is believed to have advantages over neutral P2Y 12 receptor antagonists against thrombotic diseases.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. cAMP conversion from ATP (x 1000) Inhibition of pAkt (%) control 26.7 ± 2.9 0 AR-C78511 100 nM 88 ± 12 76 ± 9 AR-C69931MX 300 nM 27.8 ± 4 9.7 ± 2.4 AR-C66096 3 µM 40 ± 6 44 ± 5 AR-C67085 1 µM 48 ± 6 24 ± 4 AR-C69581 3µM 44 ± 4 17 ± 4
This article has not been copyedited and formatted. The final version may differ from this version. at ASPET Journals on January 6, 2018 molpharm.aspetjournals.org Downloaded from
Fig. 6
This article has not been copyedited and formatted. The final version may differ from this version.
